Alexandria Venture Investments, Brace Pharma Capital and Takeda Ventures have contributed to the round, which included a $15m commitment from Eli Lilly made earlier this year.
US-based biotechnology developer Avidity Biosciences closed a $100m series C round yesterday backed by pharmaceutical firms EMS and Takeda, which contributed through respective subsidiaries Brace Pharma Capital and Takeda Ventures.
Drug manufacturer ST Pharm also participated, as did life science real estate developer Alexandria Real Estate Equities’ Alexandria Venture Investments unit. The round included a $15m commitment from pharmaceutical company Eli Lilly announced in April this year.
RTW Investments led the series C round, while Cormorant Asset Management, LP,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
